L-18F-DOPA-PET bei Parkinson-Plus-Syndromen zum Nachweis einer gestörten präsynaptischen dopaminergen Funktion
Identifieur interne :
001093 ( PascalFrancis/Corpus );
précédent :
001092;
suivant :
001094
L-18F-DOPA-PET bei Parkinson-Plus-Syndromen zum Nachweis einer gestörten präsynaptischen dopaminergen Funktion
Auteurs : M. Cordes ;
B. J. Snow ;
H. Takahashi ;
P. Schofield ;
S. Cooper ;
V. Sossi ;
S. Morrison ;
D. B. CalneSource :
-
Nuclear-Medizin [ 0029-5566 ] ; 1992.
RBID : Pascal:92-0566899
Descripteurs français
- Pascal (Inist)
- Maladie dégénérative,
Homme,
Physiopathologie,
Diagnostic,
Etude comparative,
Etude statistique,
Exploration radioisotopique,
Tomoscintigraphie,
Radiothérapie,
Parkinson maladie,
Produit radioisotopique,
Agent scintigraphique,
Corps strié,
Modèle mathématique,
Médecine nucléaire,
Dopa.
English descriptors
- KwdEn :
- Comparative study,
Corpus striatum,
Degenerative disease,
Diagnosis,
Dopa,
Human,
Mathematical model,
Nuclear medicine,
Parkinson disease,
Pathophysiology,
Positron emission tomography,
Radionuclide study,
Radiopharmaceuticals,
Radiotherapy,
Scintigraphic agent,
Statistical study.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
| A01 | 01 | 1 | | @0 0029-5566 |
|---|
| A02 | 01 | | | @0 NMIMAX |
|---|
| A03 | | 1 | | @0 Nucl.-Med. |
|---|
| A05 | | | | @2 31 |
|---|
| A06 | | | | @2 2 |
|---|
| A08 | 01 | 1 | GER | @1 L-18F-DOPA-PET bei Parkinson-Plus-Syndromen zum Nachweis einer gestörten präsynaptischen dopaminergen Funktion |
|---|
| A11 | 01 | 1 | | @1 CORDES (M.) |
|---|
| A11 | 02 | 1 | | @1 SNOW (B. J.) |
|---|
| A11 | 03 | 1 | | @1 TAKAHASHI (H.) |
|---|
| A11 | 04 | 1 | | @1 SCHOFIELD (P.) |
|---|
| A11 | 05 | 1 | | @1 COOPER (S.) |
|---|
| A11 | 06 | 1 | | @1 SOSSI (V.) |
|---|
| A11 | 07 | 1 | | @1 MORRISON (S.) |
|---|
| A11 | 08 | 1 | | @1 CALNE (D. B.) |
|---|
| A14 | 01 | | | @1 Univ. hosp., univ. British Columbia, fac. medicine, neurodegenerative disorders cent. @2 Vancouver V6T 1W5 @3 CAN |
|---|
| A20 | | | | @1 43-47 |
|---|
| A21 | | | | @1 1992 |
|---|
| A23 | 01 | | | @0 GER |
|---|
| A24 | 01 | | | @0 eng |
|---|
| A43 | 01 | | | @1 INIST @2 1709 @5 354000029619860020 |
|---|
| A44 | | | | @0 0000 |
|---|
| A45 | | | | @0 16 ref. |
|---|
| A47 | 01 | 1 | | @0 92-0566899 |
|---|
| A60 | | | | @1 P |
|---|
| A61 | | | | @0 A |
|---|
| A64 | | 1 | | @0 Nuclear-Medizin |
|---|
| A66 | 01 | | | @0 DEU |
|---|
| A68 | 01 | 1 | ENG | @1 L-18F-DOPA PET for the assessment of disturbed nigrostriatal function in parkinsonism-plus syndromes |
|---|
| C02 | 01 | X | | @0 002B17G |
|---|
| C03 | 01 | X | FRE | @0 Maladie dégénérative |
|---|
| C03 | 01 | X | ENG | @0 Degenerative disease |
|---|
| C03 | 01 | X | SPA | @0 Enfermedad degenerativa |
|---|
| C03 | 02 | X | FRE | @0 Homme |
|---|
| C03 | 02 | X | ENG | @0 Human |
|---|
| C03 | 02 | X | SPA | @0 Hombre |
|---|
| C03 | 03 | X | FRE | @0 Physiopathologie |
|---|
| C03 | 03 | X | ENG | @0 Pathophysiology |
|---|
| C03 | 03 | X | SPA | @0 Fisiopatología |
|---|
| C03 | 04 | X | FRE | @0 Diagnostic |
|---|
| C03 | 04 | X | ENG | @0 Diagnosis |
|---|
| C03 | 04 | X | SPA | @0 Diagnóstico |
|---|
| C03 | 05 | X | FRE | @0 Etude comparative |
|---|
| C03 | 05 | X | ENG | @0 Comparative study |
|---|
| C03 | 05 | X | GER | @0 Vergleich |
|---|
| C03 | 05 | X | SPA | @0 Estudio comparativo |
|---|
| C03 | 06 | X | FRE | @0 Etude statistique |
|---|
| C03 | 06 | X | ENG | @0 Statistical study |
|---|
| C03 | 06 | X | SPA | @0 Estudio estadístico |
|---|
| C03 | 07 | X | FRE | @0 Exploration radioisotopique |
|---|
| C03 | 07 | X | ENG | @0 Radionuclide study |
|---|
| C03 | 07 | X | SPA | @0 Exploración radioisotópica |
|---|
| C03 | 08 | X | FRE | @0 Tomoscintigraphie |
|---|
| C03 | 08 | X | ENG | @0 Positron emission tomography |
|---|
| C03 | 08 | X | SPA | @0 Tomocentelleografía |
|---|
| C03 | 09 | X | FRE | @0 Radiothérapie |
|---|
| C03 | 09 | X | ENG | @0 Radiotherapy |
|---|
| C03 | 09 | X | SPA | @0 Radioterapia |
|---|
| C03 | 10 | X | FRE | @0 Parkinson maladie |
|---|
| C03 | 10 | X | ENG | @0 Parkinson disease |
|---|
| C03 | 10 | X | SPA | @0 Parkinson enfermedad |
|---|
| C03 | 11 | X | FRE | @0 Produit radioisotopique |
|---|
| C03 | 11 | X | ENG | @0 Radiopharmaceuticals |
|---|
| C03 | 11 | X | SPA | @0 Producto radioisotópico |
|---|
| C03 | 12 | X | FRE | @0 Agent scintigraphique |
|---|
| C03 | 12 | X | ENG | @0 Scintigraphic agent |
|---|
| C03 | 12 | X | SPA | @0 Agente centelleográfico |
|---|
| C03 | 13 | X | FRE | @0 Corps strié |
|---|
| C03 | 13 | X | ENG | @0 Corpus striatum |
|---|
| C03 | 13 | X | SPA | @0 Cuerpo estriado |
|---|
| C03 | 14 | X | FRE | @0 Modèle mathématique |
|---|
| C03 | 14 | X | ENG | @0 Mathematical model |
|---|
| C03 | 14 | X | GER | @0 Mathematisches Modell |
|---|
| C03 | 14 | X | SPA | @0 Modelo matemático |
|---|
| C03 | 15 | X | FRE | @0 Médecine nucléaire |
|---|
| C03 | 15 | X | ENG | @0 Nuclear medicine |
|---|
| C03 | 15 | X | SPA | @0 Medicina nuclear |
|---|
| C03 | 16 | X | FRE | @0 Dopa @2 NK @2 FR |
|---|
| C03 | 16 | X | ENG | @0 Dopa @2 NK @2 FR |
|---|
| C03 | 16 | X | SPA | @0 Dopa @2 NK @2 FR |
|---|
| C07 | 01 | X | FRE | @0 Système nerveux pathologie |
|---|
| C07 | 01 | X | ENG | @0 Nervous system diseases |
|---|
| C07 | 01 | X | SPA | @0 Sistema nervioso patología |
|---|
| C07 | 02 | X | FRE | @0 Encéphale pathologie |
|---|
| C07 | 02 | X | ENG | @0 Cerebral disorder |
|---|
| C07 | 02 | X | SPA | @0 Encéfalo patología |
|---|
| C07 | 03 | X | FRE | @0 Système nerveux central pathologie @4 INC |
|---|
| N21 | | | | @1 306 |
|---|
|
|---|
Format Inist (serveur)
| NO : | PASCAL 92-0566899 INIST |
|---|
| ET : | (L-18F-DOPA PET for the assessment of disturbed nigrostriatal function in parkinsonism-plus syndromes) |
|---|
| GT : | L-18F-DOPA-PET bei Parkinson-Plus-Syndromen zum Nachweis einer gestörten präsynaptischen dopaminergen Funktion |
|---|
| AU : | CORDES (M.); SNOW (B. J.); TAKAHASHI (H.); SCHOFIELD (P.); COOPER (S.); SOSSI (V.); MORRISON (S.); CALNE (D. B.) |
|---|
| AF : | Univ. hosp., univ. British Columbia, fac. medicine, neurodegenerative disorders cent./Vancouver V6T 1W5/Canada |
|---|
| DT : | Publication en série; Niveau analytique |
|---|
| SO : | Nuclear-Medizin; ISSN 0029-5566; Coden NMIMAX; Allemagne; Da. 1992; Vol. 31; No. 2; Pp. 43-47; Abs. anglais; Bibl. 16 ref. |
|---|
| LA : | Allemand |
|---|
| CC : | 002B17G |
|---|
| FD : | Maladie dégénérative; Homme; Physiopathologie; Diagnostic; Etude comparative; Etude statistique; Exploration radioisotopique; Tomoscintigraphie; Radiothérapie; Parkinson maladie; Produit radioisotopique; Agent scintigraphique; Corps strié; Modèle mathématique; Médecine nucléaire; Dopa |
|---|
| FG : | Système nerveux pathologie; Encéphale pathologie; Système nerveux central pathologie |
|---|
| ED : | Degenerative disease; Human; Pathophysiology; Diagnosis; Comparative study; Statistical study; Radionuclide study; Positron emission tomography; Radiotherapy; Parkinson disease; Radiopharmaceuticals; Scintigraphic agent; Corpus striatum; Mathematical model; Nuclear medicine; Dopa |
|---|
| EG : | Nervous system diseases; Cerebral disorder |
|---|
| GD : | Vergleich; Mathematisches Modell |
|---|
| SD : | Enfermedad degenerativa; Hombre; Fisiopatología; Diagnóstico; Estudio comparativo; Estudio estadístico; Exploración radioisotópica; Tomocentelleografía; Radioterapia; Parkinson enfermedad; Producto radioisotópico; Agente centelleográfico; Cuerpo estriado; Modelo matemático; Medicina nuclear; Dopa |
|---|
| LO : | INIST-1709.354000029619860020 |
|---|
| ID : | 92-0566899 |
|---|
Links to Exploration step
Pascal:92-0566899
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="GER" level="a">L-<sup>18</sup>
F-DOPA-PET bei Parkinson-Plus-Syndromen zum Nachweis einer gestörten präsynaptischen dopaminergen Funktion</title><author><name sortKey="Cordes, M" sort="Cordes, M" uniqKey="Cordes M" first="M." last="Cordes">M. Cordes</name>
<affiliation><inist:fA14 i1="01"><s1>Univ. hosp., univ. British Columbia, fac. medicine, neurodegenerative disorders cent.</s1>
<s2>Vancouver V6T 1W5</s2>
<s3>CAN</s3>
</inist:fA14><author><name sortKey="Snow, B J" sort="Snow, B J" uniqKey="Snow B" first="B. J." last="Snow">B. J. Snow</name>
</author><author><name sortKey="Takahashi, H" sort="Takahashi, H" uniqKey="Takahashi H" first="H." last="Takahashi">H. Takahashi</name>
</author><author><name sortKey="Schofield, P" sort="Schofield, P" uniqKey="Schofield P" first="P." last="Schofield">P. Schofield</name>
</author><author><name sortKey="Cooper, S" sort="Cooper, S" uniqKey="Cooper S" first="S." last="Cooper">S. Cooper</name>
</author><author><name sortKey="Sossi, V" sort="Sossi, V" uniqKey="Sossi V" first="V." last="Sossi">V. Sossi</name>
</author><author><name sortKey="Morrison, S" sort="Morrison, S" uniqKey="Morrison S" first="S." last="Morrison">S. Morrison</name>
</author><author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
</author><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">92-0566899</idno>
<date when="1992">1992</date>
<idno type="stanalyst">PASCAL 92-0566899 INIST</idno>
<idno type="RBID">Pascal:92-0566899</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001093</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="GER" level="a">L-<sup>18</sup>
F-DOPA-PET bei Parkinson-Plus-Syndromen zum Nachweis einer gestörten präsynaptischen dopaminergen Funktion</title><author><name sortKey="Cordes, M" sort="Cordes, M" uniqKey="Cordes M" first="M." last="Cordes">M. Cordes</name>
<affiliation><inist:fA14 i1="01"><s1>Univ. hosp., univ. British Columbia, fac. medicine, neurodegenerative disorders cent.</s1>
<s2>Vancouver V6T 1W5</s2>
<s3>CAN</s3>
</inist:fA14><author><name sortKey="Snow, B J" sort="Snow, B J" uniqKey="Snow B" first="B. J." last="Snow">B. J. Snow</name>
</author><author><name sortKey="Takahashi, H" sort="Takahashi, H" uniqKey="Takahashi H" first="H." last="Takahashi">H. Takahashi</name>
</author><author><name sortKey="Schofield, P" sort="Schofield, P" uniqKey="Schofield P" first="P." last="Schofield">P. Schofield</name>
</author><author><name sortKey="Cooper, S" sort="Cooper, S" uniqKey="Cooper S" first="S." last="Cooper">S. Cooper</name>
</author><author><name sortKey="Sossi, V" sort="Sossi, V" uniqKey="Sossi V" first="V." last="Sossi">V. Sossi</name>
</author><author><name sortKey="Morrison, S" sort="Morrison, S" uniqKey="Morrison S" first="S." last="Morrison">S. Morrison</name>
</author><author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
</author><series><title level="j" type="main">Nuclear-Medizin</title>
<title level="j" type="abbreviated">Nucl.-Med.</title>
<idno type="ISSN">0029-5566</idno>
<imprint><date when="1992">1992</date>
</imprint><seriesStmt><title level="j" type="main">Nuclear-Medizin</title>
<title level="j" type="abbreviated">Nucl.-Med.</title>
<idno type="ISSN">0029-5566</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Comparative study</term>
<term>Corpus striatum</term>
<term>Degenerative disease</term>
<term>Diagnosis</term>
<term>Dopa</term>
<term>Human</term>
<term>Mathematical model</term>
<term>Nuclear medicine</term>
<term>Parkinson disease</term>
<term>Pathophysiology</term>
<term>Positron emission tomography</term>
<term>Radionuclide study</term>
<term>Radiopharmaceuticals</term>
<term>Radiotherapy</term>
<term>Scintigraphic agent</term>
<term>Statistical study</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie dégénérative</term>
<term>Homme</term>
<term>Physiopathologie</term>
<term>Diagnostic</term>
<term>Etude comparative</term>
<term>Etude statistique</term>
<term>Exploration radioisotopique</term>
<term>Tomoscintigraphie</term>
<term>Radiothérapie</term>
<term>Parkinson maladie</term>
<term>Produit radioisotopique</term>
<term>Agent scintigraphique</term>
<term>Corps strié</term>
<term>Modèle mathématique</term>
<term>Médecine nucléaire</term>
<term>Dopa</term>
</keywords><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0029-5566</s0>
</fA01><fA02 i1="01"><s0>NMIMAX</s0>
</fA02><fA03 i2="1"><s0>Nucl.-Med.</s0>
</fA03><fA08 i1="01" i2="1" l="GER"><s1>L-<sup>18</sup>
F-DOPA-PET bei Parkinson-Plus-Syndromen zum Nachweis einer gestörten präsynaptischen dopaminergen Funktion</s1><fA11 i1="01" i2="1"><s1>CORDES (M.)</s1>
</fA11><fA11 i1="02" i2="1"><s1>SNOW (B. J.)</s1>
</fA11><fA11 i1="03" i2="1"><s1>TAKAHASHI (H.)</s1>
</fA11><fA11 i1="04" i2="1"><s1>SCHOFIELD (P.)</s1>
</fA11><fA11 i1="05" i2="1"><s1>COOPER (S.)</s1>
</fA11><fA11 i1="06" i2="1"><s1>SOSSI (V.)</s1>
</fA11><fA11 i1="07" i2="1"><s1>MORRISON (S.)</s1>
</fA11><fA11 i1="08" i2="1"><s1>CALNE (D. B.)</s1>
</fA11><fA14 i1="01"><s1>Univ. hosp., univ. British Columbia, fac. medicine, neurodegenerative disorders cent.</s1>
<s2>Vancouver V6T 1W5</s2>
<s3>CAN</s3>
</fA14><fA20><s1>43-47</s1>
</fA20><fA21><s1>1992</s1>
</fA21><fA23 i1="01"><s0>GER</s0>
</fA23><fA24 i1="01"><s0>eng</s0>
</fA24><fA43 i1="01"><s1>INIST</s1>
<s2>1709</s2>
<s5>354000029619860020</s5>
</fA43><fA44><s0>0000</s0>
</fA44><fA45><s0>16 ref.</s0>
</fA45><fA47 i1="01" i2="1"><s0>92-0566899</s0>
</fA47><fA64 i2="1"><s0>Nuclear-Medizin</s0>
</fA64><fA66 i1="01"><s0>DEU</s0>
</fA66><fA68 i1="01" i2="1" l="ENG"><s1>L-<sup>18</sup>
F-DOPA PET for the assessment of disturbed nigrostriatal function in parkinsonism-plus syndromes</s1><fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Degenerative disease</s0>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Homme</s0>
</fC03><fC03 i1="02" i2="X" l="ENG"><s0>Human</s0>
</fC03><fC03 i1="02" i2="X" l="SPA"><s0>Hombre</s0>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Physiopathologie</s0>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Pathophysiology</s0>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Fisiopatología</s0>
</fC03><fC03 i1="04" i2="X" l="FRE"><s0>Diagnostic</s0>
</fC03><fC03 i1="04" i2="X" l="ENG"><s0>Diagnosis</s0>
</fC03><fC03 i1="04" i2="X" l="SPA"><s0>Diagnóstico</s0>
</fC03><fC03 i1="05" i2="X" l="FRE"><s0>Etude comparative</s0>
</fC03><fC03 i1="05" i2="X" l="ENG"><s0>Comparative study</s0>
</fC03><fC03 i1="05" i2="X" l="GER"><s0>Vergleich</s0>
</fC03><fC03 i1="05" i2="X" l="SPA"><s0>Estudio comparativo</s0>
</fC03><fC03 i1="06" i2="X" l="FRE"><s0>Etude statistique</s0>
</fC03><fC03 i1="06" i2="X" l="ENG"><s0>Statistical study</s0>
</fC03><fC03 i1="06" i2="X" l="SPA"><s0>Estudio estadístico</s0>
</fC03><fC03 i1="07" i2="X" l="FRE"><s0>Exploration radioisotopique</s0>
</fC03><fC03 i1="07" i2="X" l="ENG"><s0>Radionuclide study</s0>
</fC03><fC03 i1="07" i2="X" l="SPA"><s0>Exploración radioisotópica</s0>
</fC03><fC03 i1="08" i2="X" l="FRE"><s0>Tomoscintigraphie</s0>
</fC03><fC03 i1="08" i2="X" l="ENG"><s0>Positron emission tomography</s0>
</fC03><fC03 i1="08" i2="X" l="SPA"><s0>Tomocentelleografía</s0>
</fC03><fC03 i1="09" i2="X" l="FRE"><s0>Radiothérapie</s0>
</fC03><fC03 i1="09" i2="X" l="ENG"><s0>Radiotherapy</s0>
</fC03><fC03 i1="09" i2="X" l="SPA"><s0>Radioterapia</s0>
</fC03><fC03 i1="10" i2="X" l="FRE"><s0>Parkinson maladie</s0>
</fC03><fC03 i1="10" i2="X" l="ENG"><s0>Parkinson disease</s0>
</fC03><fC03 i1="10" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
</fC03><fC03 i1="11" i2="X" l="FRE"><s0>Produit radioisotopique</s0>
</fC03><fC03 i1="11" i2="X" l="ENG"><s0>Radiopharmaceuticals</s0>
</fC03><fC03 i1="11" i2="X" l="SPA"><s0>Producto radioisotópico</s0>
</fC03><fC03 i1="12" i2="X" l="FRE"><s0>Agent scintigraphique</s0>
</fC03><fC03 i1="12" i2="X" l="ENG"><s0>Scintigraphic agent</s0>
</fC03><fC03 i1="12" i2="X" l="SPA"><s0>Agente centelleográfico</s0>
</fC03><fC03 i1="13" i2="X" l="FRE"><s0>Corps strié</s0>
</fC03><fC03 i1="13" i2="X" l="ENG"><s0>Corpus striatum</s0>
</fC03><fC03 i1="13" i2="X" l="SPA"><s0>Cuerpo estriado</s0>
</fC03><fC03 i1="14" i2="X" l="FRE"><s0>Modèle mathématique</s0>
</fC03><fC03 i1="14" i2="X" l="ENG"><s0>Mathematical model</s0>
</fC03><fC03 i1="14" i2="X" l="GER"><s0>Mathematisches Modell</s0>
</fC03><fC03 i1="14" i2="X" l="SPA"><s0>Modelo matemático</s0>
</fC03><fC03 i1="15" i2="X" l="FRE"><s0>Médecine nucléaire</s0>
</fC03><fC03 i1="15" i2="X" l="ENG"><s0>Nuclear medicine</s0>
</fC03><fC03 i1="15" i2="X" l="SPA"><s0>Medicina nuclear</s0>
</fC03><fC03 i1="16" i2="X" l="FRE"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
</fC03><fC03 i1="16" i2="X" l="ENG"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
</fC03><fC03 i1="16" i2="X" l="SPA"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
</fC03><fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
</fC07><fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
</fC07><fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
</fC07><fC07 i1="02" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
</fC07><fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
</fC07><fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
</fC07><fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s4>INC</s4>
</fC07><fN21><s1>306</s1>
</fN21><server><NO>PASCAL 92-0566899 INIST</NO>
<ET>(L-<sup>18</sup>
F-DOPA PET for the assessment of disturbed nigrostriatal function in parkinsonism-plus syndromes)</ET><GT>L-<sup>18</sup>
F-DOPA-PET bei Parkinson-Plus-Syndromen zum Nachweis einer gestörten präsynaptischen dopaminergen Funktion</GT><AU>CORDES (M.); SNOW (B. J.); TAKAHASHI (H.); SCHOFIELD (P.); COOPER (S.); SOSSI (V.); MORRISON (S.); CALNE (D. B.)</AU>
<AF>Univ. hosp., univ. British Columbia, fac. medicine, neurodegenerative disorders cent./Vancouver V6T 1W5/Canada</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Nuclear-Medizin; ISSN 0029-5566; Coden NMIMAX; Allemagne; Da. 1992; Vol. 31; No. 2; Pp. 43-47; Abs. anglais; Bibl. 16 ref.</SO>
<LA>Allemand</LA>
<CC>002B17G</CC>
<FD>Maladie dégénérative; Homme; Physiopathologie; Diagnostic; Etude comparative; Etude statistique; Exploration radioisotopique; Tomoscintigraphie; Radiothérapie; Parkinson maladie; Produit radioisotopique; Agent scintigraphique; Corps strié; Modèle mathématique; Médecine nucléaire; Dopa</FD>
<FG>Système nerveux pathologie; Encéphale pathologie; Système nerveux central pathologie</FG>
<ED>Degenerative disease; Human; Pathophysiology; Diagnosis; Comparative study; Statistical study; Radionuclide study; Positron emission tomography; Radiotherapy; Parkinson disease; Radiopharmaceuticals; Scintigraphic agent; Corpus striatum; Mathematical model; Nuclear medicine; Dopa</ED>
<EG>Nervous system diseases; Cerebral disorder</EG>
<GD>Vergleich; Mathematisches Modell</GD>
<SD>Enfermedad degenerativa; Hombre; Fisiopatología; Diagnóstico; Estudio comparativo; Estudio estadístico; Exploración radioisotópica; Tomocentelleografía; Radioterapia; Parkinson enfermedad; Producto radioisotópico; Agente centelleográfico; Cuerpo estriado; Modelo matemático; Medicina nuclear; Dopa</SD>
<LO>INIST-1709.354000029619860020</LO>
<ID>92-0566899</ID>
</server>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001093 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001093 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:92-0566899
|texte= L-18F-DOPA-PET bei Parkinson-Plus-Syndromen zum Nachweis einer gestörten präsynaptischen dopaminergen Funktion
}}
| This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022 |  |
